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University of Montpellier 1, UFR de Médecine, Montpellier, FranceMultiple myeloma (MM) is a plasma–cell malignancy with a high de- bone morrow). SNaPshot method is ready-to-use, faster and present
gree of biological and genetic heterogeneity at presentation and a great
variability in terms of clinical outcome in response to chemotherapy.
Over the last decades, the incorporation of novel agents (immunomod-
ulatory drugs and proteasome inhibitors) with high-dose chemotherapy
followedby autologous stemcell transplantation in eligible patients has im-
proved the survival outcomes for myeloma patients (Barlogie et al., 2014).
Chromosomal abnormalities include recurrent 14q32 translocations
(involving either CCND1, MMSET and FGFR3, CCND3, c-MAF or MAFB),
hyperdiploidy, full or partial deletion of chromosomes 13 or 17 and
1q21 ampliﬁcations (Morgan et al., 2012). However, these chromosom-
al abnormalities are also observed in monoclonal gammopathy of un-
known signiﬁcance and genetic mutations have also been described as
potent drivers of MM pathogenesis. Signiﬁcant mutated genes were re-
ported in MM including KRAS (23%), NRAS (20%), FAM46C (11%), TP53
(8%), DIS3 (11%), BRAF (6%), TRAF3 (5%) and PRDM1 (5%) (Chapman
et al., 2011; Lohr et al., 2014). This heterogeneity is also translated at a
subclonal level with a characterized complex clonal evolution during
the progression of the disease (Bolli et al., 2014; Melchor et al., 2014).
This high heterogeneity in MM emphasizes the requirement of tools
for rapid identiﬁcation ofmutations constituting potent therapeutic tar-
gets in a personalized therapy approach.
O'Donnell and colleagues reported the interest of a Clinical Laborato-
ry Improvement Amendments-approved, high-throughput, genotyping
platform to determine the mutation status of a panel of known cancer
genes in MM (O'Donnell et al., 2014). The method uses a highly sen-
sitivemultiplexed PCR-based assay to simultaneously identify 70 genet-
ic loci frequently mutated in 15 cancer genes including NRAS, KRAS,
TP53, BRAF and HRAS. The interest of their ready-to-use assay was in-
vestigated in 67 samples of patients with MM including a majority of
samples collected at relapse. A candidate mutation was detected in 26
out of 67 tumor samples including KRAS (15/26), NRAS (6/26), TP53
(2/26), BRAF (2/26) and HRAS (1/26) mutations. Signiﬁcant association
between the occurrence of mutations and heavy-chain disease has been
found. Interestingly, this methodology was performed on total bone
marrow, without plasma cell puriﬁcation, and displayed an overall sen-
sitivity of 5% (requiring the presence of 10% clonal plasma cells withinDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.11.008.
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clinical practice. However, a limitation is linked to the fact that only al-
ready identiﬁedmutations can be investigated. Furthermore, addition of
several genes described as frequently mutated in MM like DIS3,
FAM46C, TRAF3 and PRDM1 could be beneﬁcial to improve the assay.
The assay developed by O'Donnell et al. (2014) appears useful for
rapid identiﬁcation ofmutations representing potential therapeutic tar-
gets in tumors with complex clonal evolution. Development of patient-
speciﬁc personalized therapy may limit the side effects of treatment,
improving compliance with dosing regimens and overall quality of
life. The huge amounts of biological and genetic data generated by
high-throughput technologies will facilitate pharmacogenomic prog-
ress, suggest novel druggable molecules, and support the design of fu-
ture therapeutic strategies. Identiﬁcation of BRAF activating mutation
in MM has stimulated clinical exploration of BRAF inhibitors (Lohr
et al., 2014; Andrulis et al., 2013). Recently, Andrulis et al. reported
durable response in a patient harboring BRAF V600E mutation with
relapsed MM refractory to all approved therapeutic options after treat-
ment with vemurafenib (Andrulis et al., 2013). An open-label multi-
center study investigating the efﬁcacy and safety of vemurafenib in
patients with BRAF mutation-positive cancers, including MM, is cur-
rently recruiting participants. Oncogenic mutations in MM could also
be linked with response to therapy. More recently, Mulligan et al. dem-
onstrated that NRAS mutation, but not KRAS, is associated with a signiﬁ-
cantly reduced sensitivity to single-agent bortezomib therapy as well as
shorter time to progression in bortezomib-treated patients (Mulligan
et al., 2014). Nevertheless, NRASmutation did not impact outcome in pa-
tients treatedwith high-dose dexamethasone (Mulligan et al., 2014). This
study underlines a clinical impact of NRAS mutation in MM.
The SNaPshot assay reported by O'Donnell and colleagues is un-
doubtedly useful in clinical practice (O'Donnell et al., 2014). This
ready-to-use assay to detect major mutations in MM is an interesting
method to integrate rapid genomic analysis into clinical routine for my-
eloma patients and could be valuable for adapting targeted treatment
according to clonal evolution, during progression of the disease, in com-
bination with existing therapies.
Disclosure
The author declared that there are no conﬂicts of interest.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
14 J. Moreaux / EBioMedicine 2 (2015) 13–14References
Andrulis, M., Lehners, N., Capper, D., et al., 2013. Targeting the BRAF V600E mutation in
multiple myeloma. Cancer Discov. 3 (8), 862–869 (Aug).
Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G.J., Crowley, J., 2014. Curing mye-
loma at last: deﬁning criteria and providing the evidence. Blood 124 (20), 3043–3051.
Bolli, N., Avet-Loiseau, H., Wedge, D.C., et al., 2014. Heterogeneity of genomic evolution
and mutational proﬁles in multiple myeloma. Nat. Commun. 5, 2997 (Jan 16).
Chapman, M.A., Lawrence, M.S., Keats, J.J., et al., 2011. Initial genome sequencing and
analysis of multiple myeloma. Nature 471 (7339), 467–472.
Lohr, J.G., Stojanov, P., Carter, S.L., et al., 2014. Widespread genetic heterogeneity in mul-
tiple myeloma: implications for targeted therapy. Cancer Cell 25 (1), 91–101.Melchor, L., Brioli, A., Wardell, C.P., et al., 2014. Single-cell genetic analysis reveals the
composition of initiating clones and phylogenetic patterns of branching and parallel
evolution in myeloma. Leukemia 28 (8), 1705–1715 (Aug).
Morgan, G.J., Walker, B.A., Davies, F.E., 2012. The genetic architecture of multiple myelo-
ma. Nat. Rev. Cancer 12 (5), 335–348 (May).
Mulligan, G., Lichter, D.I., Di Bacco, A., et al., 2014. Mutation of NRAS but not KRAS signif-
icantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123
(5), 632–639.
O'Donnell, E., Mahindra, A., Yee, A.J., et al., 2014. Clinical grade “SNaPshot” genetic muta-
tion proﬁling in multiple myeloma. EBioMedicine 2, 71–73.
